Explanation: US based Conduent on 3rd Jan 2017 completed its separation from Xerox.

It has launched itself as a business process services leader with USD 6.7 billion in annual revenue.

With close to 93,000 employees in more than 40 nations, Conduent is a top Fortune 500 company.

It has expertise in transaction intensive processing, analytics and automation.

The CEO of Conduent is Ashok Vemuri.

The company handles more than 2.5 million contact centre interactions daily.

It services 8.9 million who pass through managed toll systems representing 46% of the US toll collections.

Know More About Xerox

CEO: Ursula Burns (from Jul 1, 2009 to present)

Headquarters: Norwalk, Connecticut, United States

Revenue: 18.04 billion USD (2015)

Founders: Joseph C. Wilson, Chester Carlson

5) SC has extended judicial review powers in what way on Jan 2, 2017?

a. Re-promulgation of ordinance is illegal.b. Ordinances passed by President and State Governors by bypassing legislature are not immune from judicial review.c. Both of the aboved. Neither of the above

Explanation: Researchers from Israel headed by Nobel laureate Ada E. Yonath is set to develop an effective drug to fight disease resistant pathogens,

The genetic solution to the menace of antibiotic resistance to a plethora of diseases such as TB and hospital acquired infections, it targets a bacteria called methicillin-resistant Staphylococcus aureus (MRSA).

Pathogens developing resistance to antibiotics are a real threat.

The novel molecule called Lefamulin has been found to treat diseases resistant to set of antibiotics.

This drug targets pneumonia.

Staphylococcus aureus is fast developing resistance.

This is causing new infections to patients.

Role of ribosomes to develop new generation antibiotics is being highlighted.

What are Antibiotics Drugs?

Antibiotics and similar drugs, together are called antimicrobial agents.

They have been used for the last 70 years to treat patients who have infectious diseases.

Since the 1940s, these drugs have greatly reduced illness and death from infectious diseases.

But, with the rise of antimicrobial resistance, the drugs are losing their impact.